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Type 2 diabetes (T2D) affects at least 285 million people worldwide and 
its prevalence is rapidly increasing. Understanding the molecular mecha-
nisms controlling ectopic lipid deposition and insulin response in metabolic 
tissues is essential for developing new pharmacological strategies to treat 
T2D. Obesity and overweigh are the main risk factors for developing T2D, 
but nonalcoholic fatty liver disease (NAFLD) also contributes to the patho-
genesis of T2D. To date, no specific therapy exists for NAFLD. 
In this thesis, we describe protein kinase STK25 as a new key regulator 
of ectopic lipid deposition in skeletal muscle, liver and pancreas as well as 
whole-body metabolism. We also show that treatment with Stk25 antisense 
oligonucleotides in obese mice protects against high-fat diet-induced liver 
steatosis, glucose intolerance and insulin resistance. These findings demon-
strate that inhibition of STK25 may provide new-in-class therapeutics for 
NAFLD, T2D and related metabolic complications.
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